VRDN Viridian Therapeutics13.86-0.04 (-0.3%)
VRDN Viridian Therapeutics14.28-4.56 (-24.2%)
Premarket Decliner
VRDN Viridian Therapeutics27.39-0.81-2.9%
Premarket:19.08-8.31 (-30.4%)
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease
Business WireMon, 30-Mar 7:03 AM
VRDN Viridian Therapeutics11.01-0.78 (-6.6%)
VRDN Viridian Therapeutics19.41-0.04 (-0.2%)